Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply to McShane.
Hill PC, Cobelens F, Martinez L, Garcia-Basteiro AL, Behr MA, Rangaka MX, Churchyard G, Evans T, Hanekom W, White RG. Hill PC, et al. Among authors: churchyard g. J Infect Dis. 2024 Feb 14;229(2):616. doi: 10.1093/infdis/jiad466. J Infect Dis. 2024. PMID: 37897697 No abstract available.
Measuring indirect transmission-reducing effects in tuberculosis vaccine efficacy trials: why and how?
Nelson KN, Churchyard G, Cobelens F, Hanekom WA, Hill PC, Lopman B, Mave V, Rangaka MX, Vekemans J, White RG, Wong EB, Martinez L, García-Basteiro AL. Nelson KN, et al. Among authors: churchyard g. Lancet Microbe. 2023 Aug;4(8):e651-e656. doi: 10.1016/S2666-5247(23)00112-X. Epub 2023 Jun 14. Lancet Microbe. 2023. PMID: 37329893 Free PMC article. Review.
An Aspiration to Radically Shorten Phase 3 Tuberculosis Vaccine Trials.
Hill PC, Cobelens F, Martinez L, Behr MA, Churchyard G, Evans T, Fiore-Gartland AJ, Garcia-Basteiro AL, Hanekom W, Rangaka MX, Vekemans J, White RG. Hill PC, et al. Among authors: churchyard g. J Infect Dis. 2023 Nov 2;228(9):1150-1153. doi: 10.1093/infdis/jiad356. J Infect Dis. 2023. PMID: 37607272
What is next for BCG revaccination to prevent tuberculosis?
White RG, Fiore-Gartland AJ, Hanekom WA, Vekemans J, Garcia-Basteiro AL, Churchyard G, Rangaka MX, Frick M, Behr MA, Hill PC, Mave V. White RG, et al. Among authors: churchyard g. Lancet Respir Med. 2024 Mar;12(3):e7-e8. doi: 10.1016/S2213-2600(24)00009-2. Epub 2024 Jan 22. Lancet Respir Med. 2024. PMID: 38272048 No abstract available.
Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise.
Coussens AK, Zaidi SMA, Allwood BW, Dewan PK, Gray G, Kohli M, Kredo T, Marais BJ, Marks GB, Martinez L, Ruhwald M, Scriba TJ, Seddon JA, Tisile P, Warner DF, Wilkinson RJ, Esmail H, Houben RMGJ; International Consensus for Early TB (ICE-TB) group. Coussens AK, et al. Lancet Respir Med. 2024 Mar 22:S2213-2600(24)00028-6. doi: 10.1016/S2213-2600(24)00028-6. Online ahead of print. Lancet Respir Med. 2024. PMID: 38527485 Review.
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG; HVTN 503/Phambili study team. Gray GE, et al. Among authors: churchyard g. Lancet Infect Dis. 2011 Jul;11(7):507-15. doi: 10.1016/S1473-3099(11)70098-6. Epub 2011 May 11. Lancet Infect Dis. 2011. PMID: 21570355 Free PMC article. Clinical Trial.
Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in adults successfully treated for drug-susceptible pulmonary TB: a phase 1 randomized trial.
Tait D, Diacon A, Borges ÁH, van Brakel E, Hokey D, Rutkowski KT, Hunt DJ, Russell M, Andersen PL, Kromann I, Ruhwald M, Churchyard G, Dawson R. Tait D, et al. Among authors: churchyard g. J Infect Dis. 2024 Apr 1:jiae170. doi: 10.1093/infdis/jiae170. Online ahead of print. J Infect Dis. 2024. PMID: 38557639
Performance of spirometry assessment at TB diagnosis.
Rachow A, Ivanova O, Bakuli A, Khosa C, Nhassengo P, Owolabi O, Jayasooriya S, Ntinginya NE, Sabi I, Rassool M, Bennet J, Niemann S, Mekota AM, Allwood BW, Wallis RS, Charalambous S, Hoelscher M, Churchyard G. Rachow A, et al. Among authors: churchyard g. Int J Tuberc Lung Dis. 2023 Aug 1;27(11):850-857. doi: 10.5588/ijtld.23.0040. Int J Tuberc Lung Dis. 2023. PMID: 37880896 Free PMC article.
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis.
Reid M, Agbassi YJP, Arinaminpathy N, Bercasio A, Bhargava A, Bhargava M, Bloom A, Cattamanchi A, Chaisson R, Chin D, Churchyard G, Cox H, Denkinger CM, Ditiu L, Dowdy D, Dybul M, Fauci A, Fedaku E, Gidado M, Harrington M, Hauser J, Heitkamp P, Herbert N, Herna Sari A, Hopewell P, Kendall E, Khan A, Kim A, Koek I, Kondratyuk S, Krishnan N, Ku CC, Lessem E, McConnell EV, Nahid P, Oliver M, Pai M, Raviglione M, Ryckman T, Schäferhoff M, Silva S, Small P, Stallworthy G, Temesgen Z, van Weezenbeek K, Vassall A, Velásquez GE, Venkatesan N, Yamey G, Zimmerman A, Jamison D, Swaminathan S, Goosby E. Reid M, et al. Among authors: churchyard g. Lancet. 2023 Oct 21;402(10411):1473-1498. doi: 10.1016/S0140-6736(23)01379-X. Epub 2023 Sep 13. Lancet. 2023. PMID: 37716363 Review. No abstract available.
326 results